Navigation Links
BioMS Medical to present at Sachs Associates Biotech in Europe Forum
Date:9/19/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, Sept. 19 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Tony Hesby, Executive Vice President, Corporate Affairs, will present at the Sachs Associates 8th Annual Biotech in Europe Investor Forum in Zurich, Switzerland.

WHEN: Tuesday September 23rd at 11:25am (Local Time)

WHERE: Zurich, Switzerland

About Sachs Associates Biotech in Europe Investor Forum

-------------------------------------------------------

The forum is recognized as the leading international stage for those interested in investing in the biotech and life science industry and is highly transactional, drawing together an exciting cross-section of early-stage/pre-IPO, late-stage and listed companies with leading investors, analysts, money managers and pharmas.

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide (MBP8298), is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide (MBP8298), in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2014)... 28, 2014 The American Association ... University’s School of Nursing with a very prestigious ... program. The 2014 Innovations in Professional Nursing Education ... schools and supports them as they re-envision traditional ... at AACN’s annual meeting in Washington, D.C. to ...
(Date:11/27/2014)... Research and Markets  has announced the ... 2014" report to their offering. ... Acid Industry Report 2014 is a professional and in-depth ... acid industry. The report provides a basic ... industry chain structure. The palmitic acid market analysis is ...
(Date:11/27/2014)... -- Calcivis, a medical devices company ... today announces that it has completed a first ... System. The Calcivis Caries Activity Imaging ... combination designed to transform the assessment and management ... unique, proprietary bioluminescence approach combined with a specialised ...
(Date:11/26/2014)... 26, 2014 The report on the ... segments the concerned market for revenue forecasts and market ... CAGR of 51.9% from 2013 to 2018. At the ... value of $1,415.6 million by 2018. , Browse through ... TOC for information about the market segmentation and in-depth ...
Breaking Biology Technology:American Association of Colleges of Nursing honors Fairfield University’s School of Nursing for Re-envisioning Nursing Education 2Global Palmitic Acid Industry Report 2014 2Calcivis Completes Clinical Study of Novel Caries Activity Imaging System 2Calcivis Completes Clinical Study of Novel Caries Activity Imaging System 3Global Smart Sensor Market in Building Automation is expected to reach a value of $1,415.6 million by 2018 - Report by MicroMarket Monitor 2Global Smart Sensor Market in Building Automation is expected to reach a value of $1,415.6 million by 2018 - Report by MicroMarket Monitor 3Global Smart Sensor Market in Building Automation is expected to reach a value of $1,415.6 million by 2018 - Report by MicroMarket Monitor 4
... VIENNA, Austria, November 28 f-star, an antibody,engineering company ... Modular Antibody Technology, today announced that it,has raised EUR ... of its Series,A financing round, originally co-led by Aescap ... raised in the Series A round,increases to EUR 9.0 ...
... 1-41 has significant ... and anti-amnesic benefits, GENEVA, Nov. 28 /PRNewswire-FirstCall/ - ... announce promising developments with,ANAVEX 1-41, the company,s lead drug ... 1-41 prevented oxidative stress,which damages and destroys cells and ...
... November 28 The results of a,study on ... desensitisation product, which is due to receive German ... VO52.06, which was carried out on 280,patients in ... the main evaluation criterion by,demonstrating a statistically significant ...
Cached Biology Technology:Antibody Engineering Company f-star Raises EUR 3.0 Million in a Second Closing of its Series A Financing Round From Novo A/S 2Antibody Engineering Company f-star Raises EUR 3.0 Million in a Second Closing of its Series A Financing Round From Novo A/S 3Anavex advances drug candidate for treatment of Alzheimer's disease 2Anavex advances drug candidate for treatment of Alzheimer's disease 3Anavex advances drug candidate for treatment of Alzheimer's disease 4Anavex advances drug candidate for treatment of Alzheimer's disease 5STALLERGENES: ORALAIR Grasses: Positive Results of VO52.06 Paediatric Study 2
(Date:11/4/2014)... PA) – Temple University School of Medicine announced ... winner, an initiative funded by the Bill & ... Professor of Obstetrics, Gynecology and Reproductive Sciences; and ... Temple University School of Medicine will pursue an ... "Maternal Blood Biomarkers to Assess Fetal Neurodevelopment.", Grand ...
(Date:11/4/2014)... 4, 2014   ...   Fuel3D , a developer of 3D ... round totaling $6.4 million (£4 million). This funding builds on ... this year and paves the way for the commercial launch ... The funding round was led by Chimera Partners and will ...
(Date:11/3/2014)... Research and Markets has announced the addition of a ... to their offering. This report describes ... started to play an important role in the practice of ... bone marrow transplants. Role of cells in drug discovery is ... of medical practice. Stem cells are discussed in ...
Breaking Biology News(10 mins):Temple University School of Medicine receives Grand Challenges Explorations grant 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3
... (March 18, 2009) As any parent knows, children ... University of Washington and the Monell Center indicates that ... and is related to children,s high growth rate. ... sense because when growth is rapid, caloric demands increase. ...
... Mrs. Bruce Reid recorded seeing both a male and ... 1938, Oscar McKinley Bryans observed a ruby-throated hummingbird in ... apple trees were blooming. These are just two of ... on notecards in government files. The cards record more ...
... 2009 Dr. Daniel Von Hoff, Physician-In-Chief of the ... recognizing his achievements in cancer research. Dr. Von ... Clinical Research Services at Scottsdale Healthcare, will be recognized ... special report this month in Arizona Business Magazine. ...
Cached Biology News:Liking sweets makes sense for kids 2It's for the birds 2It's for the birds 3TGen's Dr. Von Hoff wins award for cancer research 2
Human PDGF R beta MAb (Clone # PR7212)...
Zebrafish Ephrin-B2 Biotinylated Affinity Purified PAb...
Collected from 8-12 week old New Zealand or Californian rabbits. Aseptically collected and processed to minimize hemolytic activity. Pricing: $60/unit for 1 - 10 units...
One-step, microplate or cuvet, colorimetric, detection range 0.3 g/dL to 5 g/dL. Procedure: 5 min....
Biology Products: